October 10, 2017
Double Helix Technologies teams-up with Agilent Technologies to offer the SureVector Cloning System
Venice, Italy, 10th October 2017 / Sciad Newswire / Double Helix Technologies (Doulix) announced today a collaboration with Agilent Technologies Inc. (NYSE: A) to promote Agilent’s SureVector next-generation cloning kits through Doulix’s web platform. Through this partnership, synthetic biologists will be able to choose among SureVector’s standard DNA parts to design custom plasmids using Doulix’s web platform.
Agilent’s SureVector is the latest innovation in next-generation cloning. SureVector harnesses the power of synthetic biology by allowing the combination of standard validated parts to create novel vector constructs. The SureVector system enables the rapid and reliable assembly of custom plasmids for mammalian, E. coli, and yeast cells by combining Agilent’s functional DNA modules with custom genes and components.
Doulix is a comprehensive toolkit for synthetic biology that allows users to easily design, validate and synthesize custom DNA vectors. Doulix combines the convenience of pre-made standard DNA parts with the freedom of a full-fledge sequence editor. Doulix also offers a validation algorithm that allows users to review their constructs for common design flaws before proceeding to synthesis.
“Today, the unmatched flexibility of SureVector and the design capability of Doulix come together to unlock the full potential of synthetic biology” said Davide De Lucrezia, Managing Director of Doulix.
“This collaboration is an exciting step forward for SureVector,” said Laura Whitman, Global Synthetic Biology Product Manager for Agilent, “It allows researchers to create individual vectors and the ability to customise any fragment in the SureVector system.”
Agilent has been a leading provider of molecular biology tools since it acquired Stratagene in 2007. It is one of the few companies whose products address the entire workflow for molecular and synthetic biology, and “SureVector is part of Agilent’s continued commitment to providing revolutionary tools for molecular biology”, said Agilent’s Whitman.
For further information, contact:
Double Helix Technologies
Anna Simion, PR Manager
T: +39 328 79 42 731
Sciad Communications Ltd
Emma Pickup, Account Executive
T: +44 (0)20 7470 8801
Notes to Editors
Double Helix Technologies (DOULIX ™) is a trademark and a business unit of EXPLORA BIOTECH Srl dedicated to the development of innovative enabling technologies to unlock the full potential of forward biological engineering. Information about DOULIX is available at www.doulix.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide. Information about Agilent is available at www.agilent.com.